Clinical Features of Patients with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease and Isolated Seizure Symptoms

References

• Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999;72(1):1–9. doi:10.1046/j.1471-4159.1999.0720001.x
   PubMed Web of Science ®Google Scholar
• Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455–461. doi:10.1038/nrneurol.2013.118
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmunity Rev. 2016;15(4):307–324. doi:10.1016/j.autrev.2015.12.004
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858–e1869. doi:10.1212/WNL.0000000000005560
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest. 2006;116(9):2385–2392. doi:10.1172/JCI28330
   PubMed Web of Science ®Google Scholar
• Patterson K, Iglesias E, Nasrallah M, et al. Anti-MOG encephalitis mimicking small vessel CNS vasculitis. Neurol neuroimmunol neuroinflam. 2019;6(2):e538.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Vukusic S, Marignier R. Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Curr Opinion Neurol. 2019;32(3):459–466. doi:10.1097/WCO.0000000000000681
   PubMed Web of Science ®Google Scholar
• Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9):900–908. doi:10.1212/WNL.0000000000004312
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi:10.1186/s12974-016-0718-0
   PubMed Web of Science ®Google Scholar
• Huang C, Tian X, Jiang S, et al. Comparisons between infectious and autoimmune encephalitis: clinical signs, biochemistry, blood counts, and imaging findings. Neuropsychiatr Dis Treat. 2020;16:2649–2660. doi:10.2147/NDT.S274487
   PubMed Web of Science ®Google Scholar
• Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89–102.
   PubMed Web of Science ®Google Scholar
• Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. Therap Adv Neurol Disord. 2020;13:1756286420945135. doi:10.1177/1756286420945135
   Web of Science ®Google Scholar
• Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflam. 2017;4(2):e322.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Yamada K, Ogawa R, et al. The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report. J Neurol Sci. 2018;392:113–115. doi:10.1016/j.jns.2018.06.028
   PubMed Web of Science ®Google Scholar
• Hamid SHM, Whittam D, Saviour M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018;75(1):65–71. doi:10.1001/jamaneurol.2017.3196
   PubMed Web of Science ®Google Scholar
• Yao Y, Xu Y, Ren H, et al. Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: a comparative cohort study. Mult Scler Relat Disord. 2019;27:281–288. doi:10.1016/j.msard.2018.11.007
   PubMed Web of Science ®Google Scholar
• de Mol CL, Wong Y, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26(7):806–814.
   PubMed Web of Science ®Google Scholar
• Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. 2019;266(10):2481–2487. doi:10.1007/s00415-019-09440-8
   PubMed Web of Science ®Google Scholar
• Wang YF, Liu XW, Lin JM, Liang JY, Zhao XH, Wang SJ. The clinical features of FLAIR-hyperintense lesions in anti-MOG antibody associated cerebral cortical encephalitis with seizures: case reports and literature review. Front Immunol. 2021;12:582768.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo Á, Ruiz A, D’Indy H, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017;264(9):1945–1955. doi:10.1007/s00415-017-8583-z
   PubMed Web of Science ®Google Scholar
• Tokumoto K, Nishida T, Kawaguchi N, Kaneko K, Takahashi T, Takahashi Y. Electroclinical features of seizures in myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis: a case report and literature review. Seizure. 2022;98:13–18. doi:10.1016/j.seizure.2022.04.001
   PubMed Web of Science ®Google Scholar
• Foiadelli T, Gastaldi M, Scaranzin S, Franciotta D, Savasta S. Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: two paradigmatic cases and a review of the literature. Mult Scler Relat Disord. 2020;41:102011. doi:10.1016/j.msard.2020.102011
   PubMed Web of Science ®Google Scholar
• Mariotto S, Monaco S, Peschl P, et al. MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome. BMC Neurol. 2017;17(1):190. doi:10.1186/s12883-017-0971-6
   PubMedGoogle Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165. doi:10.1016/S1474-4422(12)70310-1
   PubMed Web of Science ®Google Scholar
• Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348–356. doi:10.1093/brain/awx323
   PubMed Web of Science ®Google Scholar
• Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: a systematic review. Seizure. 2018;59:72–76. doi:10.1016/j.seizure.2018.05.004
   PubMed Web of Science ®Google Scholar
• Ramanathan S, O’Grady GL, Malone S, et al. Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. Dev Med Child Neurol. 2019;61(5):610–614. doi:10.1111/dmcn.14032
   PubMed Web of Science ®Google Scholar
• Zhong R, Zhang X, Chen Q, Li M, Guo X, Lin W. Acute symptomatic seizures and risk of epilepsy in autoimmune encephalitis: a retrospective cohort study. Front Immunol. 2022;13:813174. doi:10.3389/fimmu.2022.813174
   PubMed Web of Science ®Google Scholar
• Husari KS, Dubey D. Autoimmune Epilepsy. Neurotherapeutics. 2019;16(3):685–702.
   PubMed Web of Science ®Google Scholar
• Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017;58(7):1181–1189. doi:10.1111/epi.13797
   PubMed Web of Science ®Google Scholar
• Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3):234–246. doi:10.1016/S1474-4422(19)30488-0
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128–3138. doi:10.1093/brain/awx276
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg. 2018;89(2):127–137.
   PubMed Web of Science ®Google Scholar
• Konuskan B, Yildirim M, Gocmen R, et al. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. Mult Scler Relat Disord. 2018;26:1–7. doi:10.1016/j.msard.2018.07.022
   PubMed Web of Science ®Google Scholar
• Fujimori J, Takai Y, Nakashima I, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg. 2017;88(6):534–536. doi:10.1136/jnnp-2016-315094
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-ASSOCIATED DEMYELINATION IN CHILDREN. Curr Treat Options Neurol. 2019;21(1):2. doi:10.1007/s11940-019-0541-x
   PubMed Web of Science ®Google Scholar
• Durozard P, Rico A, Boutiere C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and Aquaporin-4 antibody diseases. Ann Neurol. 2020;87(2):256–266. doi:10.1002/ana.25648
   PubMed Web of Science ®Google Scholar
• Yılmaz Ü, Edizer S, Songür ÇY, Güzin Y, Durak FS. Atypical presentation of MOG-related disease: slowly progressive behavioral and personality changes following a seizure. Mult Scler Relat Disord. 2019;36:101394. doi:10.1016/j.msard.2019.101394
   PubMed Web of Science ®Google Scholar
• Wen X, Wang B, Wang C, Han C, Guo S. A retrospective study of patients with GABAR encephalitis: therapy, disease activity and prognostic factors. Neuropsychiatr Dis Treat. 2021;17:99–110. doi:10.2147/NDT.S289942
   PubMed Web of Science ®Google Scholar